collection
MENU ▼
Read by QxMD icon Read
search

osteoporose

shared collection
11 papers 0 to 25 followers
https://www.readbyqxmd.com/read/27845341/long-term-proton-pump-inhibitor-use-is-not-associated-with-changes-in-bone-strength-and-structure
#1
Laura E Targownik, Andrew L Goertzen, Yunhua Luo, William D Leslie
OBJECTIVES: Multiple studies have reported an association between proton pump inhibitor (PPI) use and fracture. However, the causality of this association is questionable, as there is not a well defined mechanism of action, nor is there evidence of an effect on PPIs on areal bone mineral density (aBMD) using dual photon X-ray absorptiometry (DXA). It is possible that PPIs may induce changes in bone structure which would predispose to fracture in the absence of changes in aBMD. We used three-dimensional quantitative computed tomography (3D-QCT) imaging to determine if long-term PPI use was associated with structural changes in bone independent of aBMD...
November 15, 2016: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27776362/lack-of-evidence-linking-calcium-with-or-without-vitamin-d-supplementation-to-cardiovascular-disease-in-generally-healthy-adults-a-clinical-guideline-from-the-national-osteoporosis-foundation-and-the-american-society-for-preventive-cardiology
#2
Stephen L Kopecky, Douglas C Bauer, Martha Gulati, Jeri W Nieves, Andrea J Singer, Peter P Toth, James A Underberg, Taylor C Wallace, Connie M Weaver
Description: Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention of osteoporosis and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known. Methods: The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature...
October 25, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27776363/calcium-intake-and-cardiovascular-disease-risk-an-updated-systematic-review-and-meta-analysis
#3
Mei Chung, Alice M Tang, Zhuxuan Fu, Ding Ding Wang, Sydne Jennifer Newberry
Background: Conflicting evidence exists regarding potential cardiovascular risks associated with high levels of calcium intake. Purpose: To update and reanalyze 2 systematic reviews to examine the effects of calcium intake on cardiovascular disease (CVD) among generally healthy adults. Data Sources: MEDLINE; Cochrane Central Register of Controlled Trials; Scopus, including EMBASE; and previous evidence reports from English-language publications from 1966 to July 2016...
October 25, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27641143/romosozumab-treatment-in-postmenopausal-women-with-osteoporosis
#4
Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C Hofbauer, Edith Lau, E Michael Lewiecki, Akimitsu Miyauchi, Cristiano A F Zerbini, Cassandra E Milmont, Li Chen, Judy Maddox, Paul D Meisner, Cesar Libanati, Andreas Grauer
Background Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. Methods We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered subcutaneously every 6 months. The coprimary end points were the cumulative incidences of new vertebral fractures at 12 months and 24 months...
October 20, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27282091/current-role-for-bone-absorptiometry
#5
Christian Roux, Karine Briot
Bone mineral density (BMD) measurement using dual-energy X-ray absorptiometry (DXA) is a key contributor to the management of bone fragility syndromes, most notably postmenopausal osteoporosis. Experimental studies of bone biomechanics have established that an accurate marker for mechanical strength is areal BMD (aBMD, g/cm(2)). Areal BMD contributes 70% of mechanical strength at the femur and 40% at the spine. Two decades after the T-score was first introduced (World Health Organization, 1994), changes have occurred in the indications of DXA and in the interpretation of its results for the diagnosis, prognosis, and treatment of osteoporosis...
June 6, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/26841685/bone-antiresorptive-agents-benefit-glucocorticoid-users
#6
Caroline Barranco
No abstract text is available yet for this article.
March 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/26519417/the-cumulative-incidence-of-and-risk-factors-for-latent-beaking-in-patients-with-autoimmune-diseases-taking-long-term-glucocorticoids-and-bisphosphonates
#7
H Sato, N Kondo, Y Wada, T Nakatsue, S Iguchi, J Fujisawa, J J Kazama, T Kuroda, M Nakano, N Endo, I Narita
SUMMARY: The incidence of beaking, which has been reported to precede atypical femoral fracture, was high and increased over 2 years in patients with autoimmune diseases who were taking bisphosphonates and glucocorticoids. Regular femoral X-rays are strongly recommended to screen for beaking, and bisphosphonate drug holidays should be considered. INTRODUCTION: Atypical femoral fractures (AFFs) have been recently recognized as complications associated with bisphosphonate (BP) use...
March 2016: Osteoporosis International
https://www.readbyqxmd.com/read/25455041/2014-update-of-recommendations-on-the-prevention-and-treatment-of-glucocorticoid-induced-osteoporosis
#8
Karine Briot, Bernard Cortet, Christian Roux, Laurence Fardet, Vered Abitbol, Justine Bacchetta, Daniel Buchon, Francoise Debiais, Pascal Guggenbuhl, Michel Laroche, Erik Legrand, Eric Lespessailles, Christian Marcelli, Georges Weryha, Thierry Thomas
OBJECTIVES: To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). METHODS: A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations...
December 2014: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/26280231/diagnosis-and-management-of-osteoporosis
#9
Michael P Jeremiah, Brian K Unwin, Mark H Greenawald, Vincent E Casiano
Osteoporosis-related fractures affect approximately one in two white women and one in five white men in their lifetime. The impact of fractures includes loss of function, significant costs, and increased mortality. The U.S. Preventive Services Task Force recommends using dual energy x-ray absorptiometry to screen all women 65 years and older, and younger women who have an increased fracture risk as determined by the World Health Organization's FRAX Fracture Risk Assessment Tool. Although guidelines are lacking for rescreening women who have normal bone mineral density on initial screening, intervals of at least four years appear safe...
August 15, 2015: American Family Physician
https://www.readbyqxmd.com/read/25385412/glucocorticoid-induced-osteoporosis-who-to-treat-with-what-agent
#10
REVIEW
René Rizzoli, Emmanuel Biver
Among the adverse events of glucocorticoid treatment are bone loss and fractures. Despite available, effective preventive measures, many patients receiving or initiating glucocorticoid therapy are not appropriately evaluated and treated for bone health and fracture risk. Populations with, or at risk of, glucocorticoid-induced osteoporosis (GIOP) to target for these measures are defined on the basis of dose and duration of glucocorticoid therapy and bone mineral density. That patients with GIOP should be treated as early as possible is generally agreed upon; however, diversity remains in intervention thresholds and management guidelines...
February 2015: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/22523337/benefits-and-risks-of-bisphosphonate-therapy-for-osteoporosis
#11
REVIEW
Sundeep Khosla, John P Bilezikian, David W Dempster, E Michael Lewiecki, Paul D Miller, Robert M Neer, Robert R Recker, Elizabeth Shane, Dolores Shoback, John T Potts
CONTEXT: There has been considerable concern recently in the scientific and lay media regarding the benefits vs. the risks of bisphosphonates for the treatment of osteoporosis. Risks include possible associations with osteonecrosis of the jaw (ONJ) and atypical femur fractures. In this perspective, we review the use of bisphosphonates for the treatment of osteoporosis, including an objective assessment of the risks vs. the benefits of these drugs. EVIDENCE ACQUISITION: Authors' knowledge of the field and results of focused literature searches are presented...
July 2012: Journal of Clinical Endocrinology and Metabolism
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"